CLCS
Cell Source, Inc.0.4500
+0.0809+21.9%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
20.27MP/E (TTM)
-Basic EPS (TTM)
-0.16Dividend Yield
0%Recent Filings
8-K
Auditor change disclosed
Cell Source switched auditors on June 26, 2025, after CBIZ CPAs acquired Marcum's attest business effective November 1, 2024; the Audit Committee approved engaging CBIZ for the 2024 audit. Marcum's prior reports were clean except for a going concern warning. No disagreements or reportable events occurred. Smooth handover.
10-Q
Q3 FY2024 results
Cell Source trimmed Q3 operating loss to $832K from $995K y/y (derived), thanks to 30% lower R&D spend amid paused MD Anderson patient enrollment, while G&A held steady. Net loss widened to $1.4M from $1.3M, driven by higher interest on notes and derivative fair value shifts, yet YTD net loss narrowed slightly to $4.2M versus $4.3M prior year. Cash stayed flat at $23K, with $1.9M financing inflows matching $1.9M operating burn; $19M liabilities dwarf assets, past-due notes exceed $5M principal. Equity raises continue. Past-due debt poses default risk.
10-Q
Q2 FY2024 results
Cell Source ramped R&D to $820K in Q2 2024 (up 129% y/y from $366K), driven by MD Anderson patient enrollment milestones, while trimming G&A 31% y/y to $374K on lower legal costs. Operating loss widened to $1.19M (up 32% y/y), with net loss at $1.49M versus $1.24M last year as interest edged steady but debt discount amortization halved; preferred dividends added $340K drag. Cash climbed to $91K on $1.37M financing—mostly $751K Series B preferred—covering $1.30M op burn, yet $17.3M working capital hole persists amid $1.8M past-due notes. Debt stays crushing. Litigation resolved for $135K.
10-Q
Q1 FY2024 results
Cell Source narrowed its Q1 operating loss to $1.1M from $1.4M y/y, trimming G&A by 27% to $782K despite steady R&D at $356K, while net loss eased to $1.3M from $1.7M y/y on lower debt discount amortization—EPS improved to $(0.04) from $(0.05) matching 40.5M diluted shares. Cash dwindled to $23 from $22K, with $174K ops burn offset by $152K financing; liabilities swelled to $16.8M including $5.6M past-due notes and $7.5M related-party convertibles, yet post-quarter $1.2M raised via preferred stock and notes. No revenues yet. Debt overhang looms large.
10-K
FY2023 results
Cell Source posted FY2023 net loss of $5.3M, up slightly from $5.2M in FY2022, on R&D spend of $1.6M versus $2.0M prior year as MD Anderson trial advanced with nine patients achieving engraftment sans severe GvHD. Cash dwindled to $22K by year-end amid $15.6M working capital deficit; yet post-period financings added ~$1.4M via notes and preferred stock. No revenue, ongoing losses. Trial delays threaten funding.
ABCL
AbCellera Biologics Inc.
3.46-0.05
BCLI
BrainStorm Cell Therapeutics In
0.58+0.03
CCEL
Cryo-Cell International, Inc.
3.80+0.06
CELU
Celularity Inc.
1.35-0.05
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
CLLS
Cellectis S.A.
4.06-0.73
CNTX
Context Therapeutics Inc.
1.10-0.03
CVM
Cel-Sci Corporation
5.90-0.10
LCTX
Lineage Cell Therapeutics, Inc.
1.80+0.08
MRKR
Marker Therapeutics, Inc.
1.27-0.12